PepGen Inc. – NASDAQ:PEPG
PepGen stock price today
$1.24
-2.67
-68.37%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in 3 days
PepGen stock price monthly change
-76.72%
month
PepGen stock price quarterly change
-76.72%
quarter
PepGen stock price yearly change
-44.87%
year
PepGen key metrics
Market Cap | 120.60M |
Enterprise value | 14.81M |
P/E | -2.74 |
EV/Sales | N/A |
EV/EBITDA | -0.15 |
Price/Sales | N/A |
Price/Book | 0.95 |
PEG ratio | 0.10 |
EPS | -3.24 |
Revenue | N/A |
EBITDA | -85.37M |
Income | -80.32M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freePepGen stock price history
PepGen stock forecast
PepGen financial statements
| Jun 2023 | 0 | -19.52M | |
|---|---|---|---|
| Sep 2023 | 0 | -23.29M | |
| Dec 2023 | 1.66M | -19.49M | -1174.4% |
| Mar 2024 | 0 | -18.02M |
| Dec 2023 | 1.66M | -19.49M | -1174.4% |
|---|---|---|---|
| Mar 2024 | 0 | -18.02M | |
| Oct 2025 | 0 | -17.25M | |
| Dec 2025 | 0 | -17.40M |
Analysts Price target
Financials & Ratios estimates
| 2023-11-08 | -0.88 | -0.98 |
|---|---|---|
| 2024-03-06 | -1.01 | -0.82 |
| 2024-05-14 | -0.74 | -0.63 |
| Jun 2023 | 182085000 | 34.80M | 19.11% |
|---|---|---|---|
| Sep 2023 | 164271000 | 38.40M | 23.38% |
| Dec 2023 | 143052000 | 34.63M | 24.21% |
| Mar 2024 | 207000000 | 28.00M | 13.53% |
| Jun 2023 | -17.67M | -1.00M | 189 |
|---|---|---|---|
| Sep 2023 | -16.47M | -225K | -534 |
| Dec 2023 | -19.42M | -29.58M | 26 |
| Mar 2024 | -22.53M | -11.29M | 86.96M |
PepGen alternative data
| Aug 2023 | 49 |
|---|---|
| Sep 2023 | 54 |
| Oct 2023 | 54 |
| Nov 2023 | 54 |
| Dec 2023 | 63 |
| Jan 2024 | 63 |
| Feb 2024 | 63 |
| Apr 2024 | 64 |
| May 2024 | 64 |
| Jun 2024 | 65 |
| Jul 2024 | 65 |
PepGen other data
24.37%
-47.84%
of PEPG is owned by hedge funds
23
-22
3.81M
-13.20M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Jun 2023 | 0 | 31250 |
| Nov 2023 | 1694 | 0 |
| Feb 2024 | 2557593 | 0 |
| May 2024 | 0 | 10000 |
| Quarter | Transcript |
|---|---|
| Q4 2023 7 Mar 2024 | Q4 2023 Earnings Call Transcript |
| Q4 2022 25 Mar 2023 | Q4 2022 Earnings Call Transcript |
-
What's the price of PepGen stock today?
One share of PepGen stock can currently be purchased for approximately $1.24.
-
When is PepGen's next earnings date?
Unfortunately, PepGen's (PEPG) next earnings date is currently unknown.
-
Does PepGen pay dividends?
No, PepGen does not pay dividends.
-
How much money does PepGen make?
PepGen has a market capitalization of 120.60M. PepGen made a loss 78.63M US dollars in net income (profit) last year or -$0.63 on an earnings per share basis.
-
What is PepGen's stock symbol?
PepGen Inc. is traded on the NASDAQ under the ticker symbol "PEPG".
-
What is PepGen's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of PepGen?
Shares of PepGen can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
How many employees does PepGen have?
As Jul 2024, PepGen employs 65 workers, which is 2% more then previous quarter.
-
When PepGen went public?
PepGen Inc. is publicly traded company for more then 3 years since IPO on 6 May 2022.
-
What is PepGen's official website?
The official website for PepGen is pepgen.com.
-
Where are PepGen's headquarters?
PepGen is headquartered at 245 Main Street, Cambridge, MA.
-
How can i contact PepGen?
PepGen's mailing address is 245 Main Street, Cambridge, MA and company can be reached via phone at +7 817970979.
PepGen company profile:
PepGen Inc.
pepgen.comExchange:
NASDAQ
Full time employees:
76
Industry:
Biotechnology
Sector:
Healthcare
PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. The company's lead product candidate is PGN-EDO51, an EDO peptide in Phase I clinical trials to treat individuals with Duchenne muscular dystrophy (DMD). It is also developing PGN-EDODM1, an EDO peptide-conjugated PMO for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.
245 Main Street
Cambridge, MA 02142
Cambridge, MA 02142
CIK: 0001835597
ISIN: US7133171055
CUSIP: 713317105
